Regulus Therapeutics, the microRNA joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week announced that it has appointed Stelios Papadopoulos to its board of directors.
Papadopoulos recently retired from Cowen and Company, where he served as an investment banker focused on pharmaceuticals and biotechnology, according to Regulus. Before then, he was an investment banker at PaineWebber.
He also held faculty positions at New York University Medical Center and continues to be an adjunct associate professor of cell biology at that institution. He holds a PhD in biophysics and an MBA in finance from New York University.